Hansa Biopharma — April 2024
-
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
-
"Company expects revenue of SEK 54m including product sales of SEK 48m - an increase of 10% versus the prior quarter and a 234% increase versus Q1 2023"
"Q1 2024 is the first time Hansa has delivered two consecutive quarters of strong revenue and growth"
-
Hansa Biopharma stärker kassan genom riktad nyemission på 372 miljoner kronor (Finwire)
Hansa Biopharma stärker kassan genom riktad nyemission på 372 miljoner kronor - Placera.se
Hansa Biopharma stärker kassan genom riktad nyemission på 372 miljoner kronor
placera.se (www.placera.se)
"Bland investerarna som tecknat aktier finns Braidwell, Redmile Group, Fjärde AP-fonden, Sphera Healthcare, Woodline Partners, en entitet som förvaltas av Heights Capital Ireland och Maven Investment Partners."
-
Hansa Biopharma: Secures growth capital supported by two solid quarters
-
Hansa Biopharma interim report January-March 2024
• Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease
• Cash runway extended into 2026
• Evan Ballantyne joins Hansa Biopharma as Chief Financial Office
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind